TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02260011
Drug: Ipratropium bromide HFA-134a inhalation aerosol
Normalized name: ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00861042
Drug: SPM927/Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
Study: NCT00645242
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
Study: NCT02604719
Drug: Tranexamic Acid and Ethamsylate
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
Study: NCT04265534
Drug: Telaglenastat
Normalized name: Telaglenastat
DrugBank: Telaglenastat (DB15232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glutaminase Inhibitor
Study: NCT04265534
Drug: Carboplatin Chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT04265534
Drug: Pemetrexed Chemotherapy
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT04265534
Drug: Dexamethasone 4 mg
Normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For prophylaxis, orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study: NCT01615445
Drug: Resveratrol
Normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
Study: NCT02006030
Drug: ADI-PEG 20
Normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04173533
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine (CC-486) 200 mg tablet
Study: NCT04223856
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle
Study: NCT04223856
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion on Day 1 of every 3-week cycle
Study: NCT04223856
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered as IV infusion on Day 1 of each 3-week cycle
Study: NCT04223856
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle
Study: NCT04223856
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion on Days 1 and 8 of every 3 week cycle
Study: NCT00236912
Drug: levofloxacin; metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03914092
Drug: triamcinolone acetonide injection
Normalized name: triamcinolone acetonide Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ,1 mm percutaneous intralesional injection
Study: NCT04538014
Drug: Lu AF88434
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT01466114
Drug: Norethindrone
Normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
Study: NCT04220892
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg intravenous (IV) every 3 weeks
Study: NCT04220892
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 900 mg/m\^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
Study: NCT04220892
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg twice a day, by mouth.
Study: NCT00121225
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
Study: NCT00366236
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02437669
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be administered by intranasal route using mucosal atomization device.
Study: NCT01938625
Drug: Simeprevir
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
Study: NCT01938625
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
Study: NCT01938625
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
Study: NCT01938625
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
Study: NCT01938625
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
Study: NCT01349738
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
Study: NCT01380093
Drug: MS Contin (morphine sulfate, controlled release)
Normalized name: morphine sulfate Extended Release Oral Tablet [MS Contin]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
Study: NCT01380093
Drug: EMBEDA (morphine sulfate / naltrexone hydrochloride)
Normalized name: morphine sulfate / naltrexone hydrochloride Extended Release Oral Capsule [Embeda]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
Study: NCT00308620
Drug: chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg or 500mg PO (by mouth) QDay
Study: NCT04306042
Drug: Nivolumab or Pembrolizumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab or Pembrolizumab
Study: NCT03952650
Drug: Chloroquine Phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
Study: NCT02055352
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 400 mcg twice a day via Breezhaler® device
Study: NCT02055352
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone 250 mcg twice daily via Accuhaler® device
Study: NCT02055352
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150 mcg once daily via Breezhaler® device
Study: NCT02055352
Drug: Salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol 50 mcg twice daily via Diskus® device
Study: NCT03952650
Drug: Pyrimethamine
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses.
Study: NCT00333034
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01283789
Drug: Lapatinib and RAD-001
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning.
Study: NCT01822860
Drug: Hydrochlorothiazide 25 mg
Normalized name: hydrochlorothiazide 25 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01639001
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
Study: NCT03952650
Drug: Coartem
Normalized name: Coartem
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial (Coartem ) will be administered to all participants twice during the study, approximately 2 weeks prior to the first vaccination in order to clear pre-existing parasitemia that may interfere with immunity development. The second dose will be given approximately 2 weeks prior to the 3rd vaccination in order to clear any parasitemia infection that may have happened naturally during the vaccination period and prior to the follow up period.
Study: NCT01689506
Drug: Volulyte
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
Study: NCT01689506
Drug: Human Serum Albumin
Normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
Study: NCT00058370
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00058370
Drug: lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00058370
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01639001
Drug: Pemetrexed/Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
Study: NCT01639001
Drug: Pemetrexed/Carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
Study: NCT00121732
Drug: E7974
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose = 0.15 mg/m\^2 administered on Days 1, 8, 15 of 28-day cycle.
Study: NCT00121732
Drug: E7974
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose = 0.37 mg/m\^2 administered on Days 1 and 8 of 21-day cycle.
Study: NCT01573468
Drug: Tesetaxel
Normalized name: Tesetaxel
DrugBank: Tesetaxel (DB12019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
Study: NCT03063255
Drug: Obturator block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
Study: NCT00152412
Drug: Levocetirizine oral solution
Normalized name: levocetirizine Oral Solution
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01252251
Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
Normalized name: pasireotide
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
Study: NCT02039505
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab intravenous infusion
Study: NCT02039505
Drug: Vedolizumab placebo
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab placebo
Study: NCT01722331
Drug: Tildrakizumab 200 mg
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
Study: NCT01722331
Drug: Tildrakizumab 100 mg
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 100 mg/mL PFS
Study: NCT01686711
Drug: AD-4833 15 mg
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01686711
Drug: AD-4833 30 mg
Normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04236453
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally on Day 1 of treatment periods with Treatment A.
Study: NCT04236453
Drug: Darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a single dose of Darunavir orally on Day 1 of treatment periods with Treatment B.
Study: NCT04236453
Drug: Emtricitabine/Tenofovir Alafenamide
Normalized name: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally on Day 1.
Study: NCT04236453
Drug: Cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participant will receive a single dose of Cobicistat tablet orally on Day 1.
Study: NCT00887081
Drug: PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
Normalized name: PEG-IFN alfa-2A
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
Study: NCT00550238
Drug: Pimavanserin tartrate (ACP-103)
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
Study: NCT03863938
Drug: Tegoprazan 50mg
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-CAB
Study: NCT02273115
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00986778
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
Study: NCT00986778
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
Study: NCT00986778
Drug: Adefovir
Normalized name: Adefovir
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
Study: NCT02413515
Drug: Nifedipine (Adalat GITS, BAY1040)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
Study: NCT01415960
Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by im injection, twice during the study, three months apart
Study: NCT03170284
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab is prescribed by physicians as per SPC.
Study: NCT00200681
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02330029
Drug: Pinaverium
Normalized name: pinaverium
DrugBank: Pinaverium (DB09090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
Study: NCT03556761
Drug: Oral furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (Lasix), 20 milligram, PO, PO, daily
Study: NCT02330029
Drug: Radix codonopsitis
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix codonopsitis (\~10-15g)
Study: NCT02330029
Drug: Radix curcumae
Normalized name: Curcumae Radix (Curcuma Longa)
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix curcumae (\~10g)
Study: NCT00955240
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03894540
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An intravenous solution in single-use vial to be diluted for infusion.